Evidence map›Paper›PMID 31307429›Full record

ArticleBMC cancer2019

Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules.

Mahsa Rezaei, Amir Mahdi Khamaneh, Nosratollah Zarghami, Armin Vosoughi, Shahriar Hashemzadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.International journal of molecular sciences · 2020
    Article
  11. Review
  12. Article
  13. The Blood Biomarkers of Thyroid Cancer.Cancer management and research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mahsa RezaeiDepartment of General Surgery, Tabriz University of Medical Sciences, Imam Reza Hospital, Golgasht Street, Tabriz, Iran.
Amir Mahdi KhamanehDepartment of Molecular Medicine Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Nosratollah ZarghamiDepartment of Molecular Medicine Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Armin VosoughiNeurosciences Research Center (NSRC), Faculty of Medicine, Tabriz University of Medical Sciences, Imam Reza Hospital, Golgasht Street, Tabriz, Iran. vosoughi954@gmail.com.ORCID http://orcid.org/0000-0002-0151-4025
Shahriar HashemzadehDepartment of General Surgery, Tabriz University of Medical Sciences, Imam Reza Hospital, Golgasht Street, Tabriz, Iran. shahriar_90@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThyroid cancer is the most common endocrinology cancer that its incidence has increased in recent decades. miRNAs are new biomarkers in recent studies in the diagnosis and follow-up of these patients.

methodsBlood and thyroid tissue samples were obtained from two groups of included patients (PTC and benign nodules), pre- and post-operation. miRNAs were extracted from these plasma samples and were measured quantitatively. After cDNA synthesis, qPCR was carried out. Then tissue samples were investigated, and their relation to miR expression was studied. These results were analyzed by paired- and independent samples t-test, and non-parametric tests.

resultsmiR-222 and miR-181a declined in PTC patients before and after surgery, significantly (P < 0.001 for both groups), with no significant difference in control group before and after surgery (P = 0.61 for miR-222 and P = 0.06 for miR-181a). The difference between the two groups, pre-and post-operation, was statistically significant (P = 0.01 for miR-222 and P < 0.001 for miR-181a). Comparing case and control groups, pre- and post-operatively, yielded no significant difference, in miR-155-5p levels (P = 0.61 and P = 0.53, respectively). Comparing PTC and control groups before surgery showed a significant difference (P = 0.01), while no significant difference was observed comparing them after surgery, in miR146-a (P = 0.27). Our results depicted a higher miR-155-5p and miR-146a expression before surgery than after it (P < 0.001 in both groups, for both miRs). We found a significant relationship between miR-222 and BRAFV600E mutation and significantly higher levels of miR-181a with increasing tumor size in PTC patients.

conclusionmiR-222 showed overexpression in all PTC cases, which is indicative of a relation between miRNA and PTC. Also, comparing miR-181 and miR-146a showed a significant difference between cancerous and benign cases. miR-155-5p as an inflammatory factor, showed no significant changes, comparing two groups.

Indexed as

AdultBiomarkers, TumorBiopsyFemaleHumansMaleMicroRNAsMiddle AgedPostoperative PeriodPreoperative PeriodReal-Time Polymerase Chain ReactionThyroid Cancer, PapillaryThyroid NeoplasmsThyroid NoduleTranscriptomeBiomarkers, TumorMicroRNAsBenign nodulesMicroRNAPapillary thyroid carcinomaPlasma samples

Identifiers

PMID31307429
PMCPMC6631438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.